Combination of TATE and PD-1 Inhibitor in Liver Cancer (TATE-PD1)
Hepatocellular Carcinoma, Gastric Cancer
About this trial
This is an interventional treatment trial for Hepatocellular Carcinoma focused on measuring Hepatocellular carcinoma, Immune checkpoint inhibitor, Gastric cancer, Progression
Eligibility Criteria
- Patients with a confirmed diagnosis of (1) advanced HCC or (2) metastatic gastric cancer.
- Patients between ages 18 and 80
- If HCC patients, they should have progressive disease (PD) on the first line immune therapy for advanced HCC. For patients with metastatic gastric cancer, they should have failed at least one line of systemic chemotherapy and an immune checkpoint inhibitor.
- Patients with at least two liver tumor lesions with at least one with a diameter of 2 cm or bigger, which is amendable for (super-)selective TATE as the target lesion. Alternatively, patients with one intra-hepatic lesion of 2 cm or bigger and exhapetic lesion(s) are also acceptable.
- ECOG score 2 or less
- Child-Pugh scores 5-7 for HCC patients
- Patients have normal organ function.
Sites / Locations
- University of California, IrvineRecruiting
- University of Oklahoma Health Science CenterRecruiting
- Medical College of WisconsinRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Advanced Hepatocellular carcinoma
Metastatic Gastro-esophageal cancer
PD-1 inhibitor (Nivolumab 360 mg Q3W IV ) starts at day 1, and continues until progression. TATE treatment starts at day 8 for debulking up to 4 cycles. If escape lesion appears, two more TATE treatments can be given. Tirapazamine dose at 35 mg flat dose given before embolization.
PD-1 inhibitor (Nivolumab 360 mg Q3W IV) starts at day 1, and continues until progression. TATE treatment starts at day 8 for debulking up to 4 cycles. If escape lesion appears, two more TATE treatments can be given. Tirapazamine dose at 35 mg flat dose given before embolization.